PHARVARIS NV (PHVS)       2.43  +0.41 (+20.3%)

2.43  +0.41 (+20.3%)

NL00150005Y4 - Common Stock

News Image
a month ago - Market News Video

Oversold Conditions For Pharvaris (PHVS)

News Image
2 months ago - Pharvaris N.V.

Pharvaris Presents Data Supporting HAE Drug Development Strategy at the 2022 HAEi Global Leadership Workshop

ZUG, Switzerland, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
2 months ago - Pharvaris N.V.

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

ZUG, Switzerland, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
3 months ago - Pharvaris N.V.

Pharvaris Highlights Data Supporting Clinical Development Program for Hereditary Angioedema at the 2022 Bradykinin Symposium

ZUG, Switzerland, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
3 months ago - Pharvaris N.V.

Pharvaris Reports Second Quarter 2022 Financial Results and Provides Business Update

Formal letters received from FDA relating to the previously announced hold on clinical studies of PHA121 in the U.S.Top-line data anticipated in 4Q22 for...

News Image
4 months ago - Market News Video

Pharvaris Becomes Oversold (PHVS)

News Image
4 months ago - Investor's Business Daily

Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried

Shares hit their lowest point since November on the FDA's decision in HAE.

News Image
4 months ago - Pharvaris N.V.

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.

ZUG, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
5 months ago - Pharvaris N.V.

Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
5 months ago - Pharvaris N.V.

Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
6 months ago - Pharvaris N.V.

Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
6 months ago - Pharvaris N.V.

Pharvaris Participates in the Kinin 2022 Conference

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...

News Image
7 months ago - Pharvaris N.V.

Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

News Image
7 months ago - Pharvaris N.V.

Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May ...

News Image
7 months ago - Pharvaris N.V.

Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment...

News Image
7 months ago - Pharvaris N.V.

Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) --  Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...